Please login to the form below

Not currently logged in
Email:
Password:

Baxter to acquire ApaTech equity

Baxter will acquire all of ApaTech's outstanding equity for total consideration of up to $330m, in an agreement announced this week

Baxter will acquire all of ApaTech's outstanding equity for total consideration of up to $330m, in a definitive agreement announced this week. 

As part of the aquisition, Baxter will acquire Actifuse, a silicate substituted calcium phosphate synthetic bone graft material that is currently marketed in the US, EU and other select markets around the world. It will also acquire manufacturing and R&D facilities located in the UK, US and Germany.

Ron Lloyd, vice president and general manager, BioTherapeutics and Regenerative Medicine, Baxter, said: "This is a significant step in enhancing Baxter's position in the rapidly growing orthobiologics space, and our leadership in regenerative medicine. Actifuse will allow us to immediately enter the emerging bone fusion category."

ApaTech a private equity-backed, UK-based orthobiologic products company generated sales of approximately $60m in 2009. Baxter and ApaTech will work to ensure uninterrupted operations, product distribution and ongoing support and service for customers, distributors and business partners.

Simon Cartmell, CEO, ApaTech commented: "This is a great event for ApaTech, Baxter, our customers and our employees. The combination of our market presence and insights with the resources of Baxter will enable us to deliver innovative new technologies to more patients worldwide."

The agreement includes an upfront cash payment by Baxter of $240m. Baxter may make additional payments of up to $90m related to the achievement of sales milestones. The transaction is expected to close in the first quarter 2010, subject to customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

2nd March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics